A feature of the cell cycle is that the events of one cycle must be reset before the next one begins. A study now shows that the replication machinery is removed from fully replicated DNA by a conserved ubiquitin-and CDC48 (also known as p97)-dependent pathway. This explains how eukaryotic chromosomes are returned to the unreplicated state.
Terminating the replication helicase
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A feature of the cell cycle is that the events of one cycle must be reset before the next one begins. A study now shows that the replication machinery is removed from fully replicated DNA by a conserved ubiquitin-and CDC48 (also known as p97)-dependent pathway. This explains how eukaryotic chromosomes are returned to the unreplicated state.
All organisms must make a perfect copy of the genome during every cell division. For eukaryotes this involves separating the steps of DNA replication into distinct cell cycle phases. Although great strides have been made in understanding how DNA replication is initiated, we understand very little about what happens when two replication forks converge to terminate this process. Clarifying the final steps of replication is important to appreciate how DNA is fully replicated and segregated in a timely manner. Recent work now identifies an evolutionarily conserved pathway involving the E3 ubiquitin ligase complex CRL2 Lrr1 (CRL2 in Caenorhabditis elegans, and CRL2 LRR1 in Xenopus laevis) that is required for the removal of the replication apparatus when DNA synthesis is complete 1, 2 . These studies begin to explain how DNA replication is irreversibly reset before the next division.
The tight control of DNA replication within the eukaryotic cell cycle centres on the state of the six-subunit replicative helicase MCM2-7 ( Fig. 1) . For the first step in genome duplication, the DNA must be 'licensed' to replicate through the loading of MCM2-7 onto doublestranded (ds) DNA as an inactive head-to-head double hexamer (Fig. 1a) . This licensing reaction is restricted to late mitosis/early G1 phase, due to the inhibition of this process by multiple mechanisms in other phases of the cell cycle 3 . Activation of MCM2-7 double hexamers only occurs following the G1-S transition due to the accumulation of cyclin-dependent kinase (CDK) and DBF4-dependent kinase (DDK) activities. These two kinases cause major structural changes in the MCM2-7 double hexamers, resulting in separation of the two hexamers, DNA melting and strand passage, and recruitment of the helicase cofactors CDC45 and GINS, to form the CMG complex (CDC45-MCM2-7-GINS; ref. 4 ). The exact mechanism by which DDK and CDK induce all of these changes in the helicase is not fully understood but the outcome is that the active form of the replicative helicase is the CMG complex encircling the single leading strand template (Fig. 1b) .
The separation of licensing and helicase activation into distinct phases of the cell cycle (Fig. 1a,b) ensures that DNA cannot be rereplicated within a single cell cycle, but how are CMG complexes removed when DNA synthesis is complete to reset the cycle? Experiments in Xenopus laevis egg extracts 5 and in budding yeast 6 have shown that at the end of S phase the CMG complex is actively removed from chromatin. This pathway involves ubiquitylation of the helicase subunit Mcm7, which in yeast is carried out by the ubiquitin ligase SCF Dia2 (ref. 6). The polyubiquitylated CMG complex becomes a substrate for the segregase CDC48 (also called p97 or VCP) 5, 6 . CDC48 is an ATPase that can remodel and potentially unfold ubiquitylated and SUMOylated substrates 7 , although exactly how CDC48 removes CMG from chromatin is not yet known.
A key question arising from these studies is how this CMG removal pathway is specific for terminated complexes. Premature unloading of licensed (Fig. 1a) or actively replicating (Fig. 1b) Mcm2-7 complexes could be lethal. Furthermore, as the yeast Mcm7 ubiquitin ligase subunit Dia2 is not conserved beyond fungi, how is this pathway regulated in metazoans? Recent studies, using the power of reverse genetics in C. elegans and the complete replication of DNA in vitro in Xenopus egg extracts 1, 2, 8 shed light on the final events of DNA synthesis in Metazoa, completing the cycle of MCM2-7 helicase activation and deactivation ( Fig. 1) .
A major bottleneck in studying the termination of DNA replication in eukaryotes is that termination events happen asynchronously. Elegant work in Xenopus egg extracts has solved this problem using a system that can conditionally arrest the replication of a plasmid just before termination 8 . Relief of this arrest allows the synchronous convergence and termination of replication forks. This in vitro system was used to demonstrate that when two forks converge, the CMG complex transitions from unreplicated single-stranded (ss) DNA onto the newly synthesized dsDNA 8 ( Fig. 1c) . To understand what happens to this CMG complex at termination the authors performed a proteomic analysis of factors associated with chromatin during termination. This revealed that an E3 ubiquitin ligase complex CRL2 Lrr1 and CDC48/p97 (together with cofactors including Npl4 and Ufd1) are recruited to chromatin, causing Mcm7 ubiquitylation and CMG disassembly specifically after termination of DNA replication 1 . Similar results were achieved through the analysis of the replication of sperm chromatin in Xenopus egg extracts 2 . Significantly, unloading the CMG complex is sufficient to trigger the unloading of other replication factors still bound to the helicase, such as DNA polymerases, suggesting that it is the topological linkage between CMG and DNA that is key for the stability of the replisome on chromatin 1 .
To study metazoan CMG unloading in vivo, Sonneville et , demonstrate a striking evolutionary conservation of an MCM7 polyubiquitination and CDC48/p97-dependent CMG unloading pathway at termination (Fig. 1) .
Whereas downregulation of CDC-48-NPL-4-UFD-1 is sufficient to prevent CMG unloading throughout prophase during early embryonic cycles in C. elegans, CUL-2 LRR-1 downregulation did not prevent CMG unloading in late prophase, suggesting the existence of other CMG removal pathways in vivo 2 . Through further targeted RNAi screening, Sonneville et al. showed that the CDC-48 partner protein UBXN-3 is required for the late prophase removal of CMG from chromatin (Fig. 2) . This is consistent with previous observations that depletion of UBXN-3 in C. elegans causes CDC-45 and GINS accumulation on chromatin 10 . Interestingly, depletion of UBXN-3 alone has a minor effect on CMG persistence, suggesting that CUL-2 LRR-1 is the primary mechanism for CMG removal in vivo 2 . As the UBXN-3 pathway is CDC-48-dependent, but CUL-2 LRR-1 -independent it is possible that MCM7 ubiquitylation is not required for this pathway (Fig. 2) . Intriguingly, inhibition of the SUMO protease ULP-4 mimics the phenotypes of UBXN-3 downregulation 2 , although more work needs to be done to understand this pathway in mechanistic detail (Fig. 2) .
By studying CMG unloading pathways in vivo, Sonneville et al. were able to address the physiological importance of this process. For this they combined RNAi of both CMG removal pathways, CUL-2 LRR-1 together with either UBXN-3 or ULP-4. These assays showed that these two pathways are synthetically lethal in C. elegans 2 , which suggests that both pathways for CMG removal are critical in vivo (Fig. 2 ). An important area of future study will be to understand why failing to remove the CMG complex is lethal. One possibility is that CMG persistence results in re-replication, which would have significant consequences for the onset of genomic instability. Indeed depletion of FAF1 (the human orthologue of UBXN-3) leads to replication stress in human cells 10 and multiple mutations in FAF1 have been found to be associated with a wide variety of cancers 11 . Whether these effects of loss of FAF1 are linked to defects in CMG unloading are not known.
A key outcome of the in vitro studies 1, 2, 5 together with work in budding yeast 6 is that this ubiquitination and CDC48/p97-dependent removal of MCM2-7 from chromatin is specific for CMG complexes post-termination (Fig. 1) . This pathway does not remove double hexamers in G1 phase or stalled/active CMG complexes before termination. The specificity of this pathway for terminated CMG complexes is critical to ensure that DNA replication is allowed to go to completion before the MCM2-7 complexes are removed from DNA. Understanding how this specificity is achieved may lie in a structural understanding of the differences between the MCM2-7 complexes during the cell cycle 4 . -dependent, as in Xenopus, but a second pathway functions in late prophase if CUL-2 LRR-1 is inhibited. This back-up CMG removal pathway is UBXN-3-dependent, but the mechanism of action of this pathway is not clear.
SIRT2 and glycolytic enzyme acetylation in pluripotent stem cells
Tong Ming Liu and Ng Shyh-Chang
The metabolic transition from mitochondrial oxidative phosphorylation (OXPHOS) to glycolysis is critical for somatic reprogramming of induced pluripotent stem cells (iPSCs). SIRT2 has now been established as a previously unknown regulator of this metabolic transition during somatic reprogramming by controlling the acetylation status of glycolytic enzymes.
Compared with somatic fibroblasts, human pluripotent stem cells (PSCs) manifest a substantially different metabolic state, which is characterized by lower intracellular ATP levels, lower OXPHOS and oxygen consumption rates, and increased glycolysis rates 1, 2 . Glycolysis is the series of cytosolic redox reactions that rapidly catabolize each 6-carbon glucose molecule to produce two 3-carbon pyruvate molecules and two net ATP molecules. Glycolytic intermediates can also be shunted into nucleotide, amino acid or lipid synthesis. Thus, whilst it is a less efficient energy source than OXPHOS, glycolysis can generate both anabolic growth intermediates and ATP very rapidly owing to the much higher speed of glycolysis reactions. Although many mitochondrial regulatory factors, such as Drp1, PnPase and Ucp2, have been proposed to regulate this metabolic transition between human PSCs (hPSCs) and somatic cells [1] [2] [3] , the full picture of molecular mechanisms underlying this phenomenon remains controversial and incomplete 3 . In this issue of Nature Cell Biology, Cha et al. 4 have shown that SIRT2 represents another key regulator of this metabolic transition during reprogramming, and exerts its function via the acetylation of glycolytic enzymes.
To address whether acetyl-CoA and acetylation regulate this metabolic transition, Cha et al. 4 compared acetylated proteins between human embryonic stem cells (hESCs) and fibroblasts, and identified 28 hyperacetylated proteins in hESCs. The analysis further showed that five out of ten glycolytic enzymes in hESCs are hyperacetylated, namely ALDOA, GAPDH, PGK1, ENO1 and PKM. The authors then investigated which acetylation modifiers were responsible for this difference in protein Tong Ming Liu and Ng Shyh-Chang are at the Genome Institute of Singapore, 60 Biopolis Street, 138675 Singapore. e-mail: ngsc1@gis.a-star.edu.sg
